{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:08:15Z","timestamp":1794118095094,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Department of Health Research, Govt of India","award":["(T.11011\/08\/2017-HR(Part-1)\/E-office -8025571"],"award-info":[{"award-number":["(T.11011\/08\/2017-HR(Part-1)\/E-office -8025571"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40258-024-00898-w","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T23:02:51Z","timestamp":1719874971000},"page":"885-896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-Utility Analysis of TNF-\u03b1 Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment"],"prefix":"10.1007","volume":"22","author":[{"given":"Madhumitha","family":"Haridoss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Sasidharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajith","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Rajsekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnamurthy","family":"Venkataraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-767X","authenticated-orcid":false,"given":"Bhavani Shankara","family":"Bagepally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"issue":"10055","key":"898_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"issue":"8542","key":"898_CR2","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/S0140-6736(87)91672-2","volume":"1","author":"DL Scott","year":"1987","unstructured":"Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987;1(8542):1108\u201311.","journal-title":"Lancet"},{"issue":"1","key":"898_CR3","first-page":"161","volume":"2","author":"B Heidari","year":"2011","unstructured":"Heidari B. Rheumatoid arthritis: early diagnosis and treatment outcomes. Caspian J Intern Med. 2011;2(1):161\u201370.","journal-title":"Caspian J Intern Med"},{"issue":"4","key":"898_CR4","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796-806.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"898_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/rheumatology\/31.8.519","volume":"31","author":"DM van der Heijde","year":"1992","unstructured":"van der Heijde DM, van Riel PL, van Leeuwen MA, van\u2019t Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis A prospective follow-up study of 147 patients. Br J Rheumatol. 1992;31(8):519\u201325.","journal-title":"Br J Rheumatol"},{"key":"898_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/831603","volume":"2014","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Bugatti S, Biggioggero M, Caporali R. Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Res Int. 2014;2014: 831603.","journal-title":"Biomed Res Int"},{"issue":"7","key":"898_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/13543776.18.7.723","volume":"18","author":"LD Quan","year":"2008","unstructured":"Quan LD, Thiele GM, Tian J, Wang D. The development of novel therapies for rheumatoid arthritis. Expert Opin Ther Pat. 2008;18(7):723\u201338.","journal-title":"Expert Opin Ther Pat"},{"issue":"1","key":"898_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2015-209057","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis. 2017;76(1):96\u2013104.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"898_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewe R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"898_CR10","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360\u201372.","journal-title":"JAMA"},{"issue":"6","key":"898_CR11","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","volume":"76","author":"JL Nam","year":"2017","unstructured":"Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1113\u201336.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"898_CR12","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):516\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"898_CR13","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1136\/ard-2022-223356corr1","volume":"82","author":"EULAR","year":"2023","unstructured":"EULAR. Correction: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(3):e76.","journal-title":"Ann Rheum Dis"},{"key":"898_CR14","unstructured":"Indian Monetary Fund. World Economic Outlook Database. 2023."},{"key":"898_CR15","unstructured":"The World Bank. Country|India [cited 2024 05\/05\/2024]. Available from: https:\/\/data.worldbank.org\/country\/india."},{"issue":"11","key":"898_CR16","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1136\/ard.2004.034371","volume":"64","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis. 2005;64(11):1582\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"898_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13075-015-0767-2","volume":"17","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, van Vollenhoven R, Kavanaugh A, Strand V, Vencovsky J, Schiff M, et al. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Res Ther. 2015;17(1):245.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"898_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508\u201319.","journal-title":"N Engl J Med"},{"issue":"11","key":"898_CR19","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s40273-020-00937-z","volume":"38","author":"R Gidwani","year":"2020","unstructured":"Gidwani R, Russell LB. Estimating transition probabilities from published evidence: a tutorial for decision modelers. Pharmacoeconomics. 2020;38(11):1153\u201364.","journal-title":"Pharmacoeconomics"},{"key":"898_CR20","unstructured":"SRS. Abridged Life Tables. 2020 Nov 1, 2022 [cited]. Available from: https:\/\/censusindia.gov.in\/census.website\/data\/SRSALT."},{"issue":"1","key":"898_CR21","doi-asserted-by":"publisher","first-page":"15385","DOI":"10.1038\/s41598-023-42623-y","volume":"13","author":"BS Bagepally","year":"2023","unstructured":"Bagepally BS, Kumar SS, Sasidharan A, Haridoss M, Venkataraman K. Household catastrophic health expenditures for rheumatoid arthritis: a single centre study from South India. Sci Rep. 2023;13(1):15385.","journal-title":"Sci Rep"},{"key":"898_CR22","unstructured":"National Health System Cost Database for India. 2020."},{"key":"898_CR23","unstructured":"PMJAY. Health Benefit Package-2.0 https:\/\/pmjay.gov.in\/sites\/default\/files\/2019-09\/HBP%202.0%20for%20website.pdf."},{"key":"898_CR24","unstructured":"Central Government Health Scheme MoHFW, Government of India. https:\/\/cghschennai.tn.nic.in\/rate%20list%20chennai.pdf."},{"key":"898_CR25","unstructured":"Pradhan Mantri Swasthya Suraksha Yojana MoHFW, Government of India. http:\/\/pmssy-mohfw.nic.in\/index.php."},{"key":"898_CR26","unstructured":"Development. OfEC-oa. Exchange rates. 2024 [cited 2024 10\/03\/2024]. Available from: https:\/\/data.oecd.org\/conversion\/exchange-rates.htm."},{"key":"898_CR27","unstructured":"UK ER. 2024 [cited 2024 10\/03\/2024]. Available from: https:\/\/www.exchangerates.org.uk\/INR-GBP-spot-exchange-rates-history-2022.html#:~:text=This%20is%20the%20Indian%20Rupee,GBP%20on%2012%20Feb%202022."},{"issue":"8","key":"898_CR28","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jval.2023.04.004","volume":"26","author":"DD Kim","year":"2023","unstructured":"Kim DD, Do LA, Synnott PG, Lavelle TA, Prosser LA, Wong JB, et al. Developing criteria for health economic quality evaluation tool. Value Health. 2023;26(8):1225\u201334.","journal-title":"Value Health."},{"key":"898_CR29","doi-asserted-by":"crossref","unstructured":"Haridoss M, Bagepally BS. Health-related quality of life and its association with disease activity\/functional status in rheumatoid arthritis: a cross-sectional study from South India. SSRN, June. 2024.","DOI":"10.2139\/ssrn.4855891"},{"issue":"3","key":"898_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/1756-185X.14066","volume":"24","author":"M Haridoss","year":"2021","unstructured":"Haridoss M, Bagepally BS, Natarajan M. Health-related quality of life in rheumatoid arthritis: systematic review and meta-analysis of EuroQoL (EQ-5D) utility scores from Asia. Int J Rheum Dis. 2021;24(3):314\u201326.","journal-title":"Int J Rheum Dis"},{"key":"898_CR31","unstructured":"Registry C. Centre for the evaluation of value and risk in health."},{"issue":"1","key":"898_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","volume":"20","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(1):23.","journal-title":"BMC Med"},{"issue":"10","key":"898_CR33","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/rheumatology\/kew264","volume":"55","author":"JT Joensuu","year":"2016","unstructured":"Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, et al. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study. Rheumatology (Oxford). 2016;55(10):1803\u201311.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"898_CR34","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/rheumatology\/ker084","volume":"50","author":"LG Schipper","year":"2011","unstructured":"Schipper LG, Kievit W, den Broeder AA, van der Laar MA, Adang EM, Fransen J, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford). 2011;50(7):1320\u201330.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"898_CR35","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3389\/fphar.2018.00794","volume":"2018","author":"VV Boyadzieva","year":"2018","unstructured":"Boyadzieva VV, Stoilov N, Stoilov RM, Tachkov K, Kamusheva M, Mitov K, et al. Quality of life and cost study of rheumatoid arthritis therapy with biological medicines. Front Pharmacol. 2018;9:794.","journal-title":"Front Pharmacol"},{"issue":"11","key":"898_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/CEOR.S183076","volume":"2019","author":"M Fournier","year":"2019","unstructured":"Fournier M, Chen CI, Kuznik A, Proudfoot C, Mallya UG, Michaud K. Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient. Clinicoecon Outcomes Res. 2019;11:117\u201328.","journal-title":"Clinicoecon Outcomes Res."},{"key":"898_CR37","doi-asserted-by":"crossref","unstructured":"Fatemi B, Rezaei S, Taheri S, Peiravian F. Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience. Expert Rev Pharmacoecon Outcomes Res. 2021; 21(4):775\u201384","DOI":"10.1080\/14737167.2021.1834384"},{"issue":"4","key":"898_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jval.2019.12.003","volume":"23","author":"S Ghabri","year":"2020","unstructured":"Ghabri S, Binard A, Pers YM, Maunoury F, Caro JJ. Economic evaluation of sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis and inadequate response or intolerance to methotrexate in france. Value Health. 2020;23(4):461\u201370.","journal-title":"Value Health."},{"issue":"11","key":"898_CR39","first-page":"42","volume":"34","author":"A Rathore","year":"2021","unstructured":"Rathore A, Joshi S, Dash R, Nupur N, Sreenivasan S. Emergence of India as a global manufacturing hub for biosimilars. BioPharm Int. 2021;34(11):42\u20134.","journal-title":"BioPharm Int."},{"issue":"5","key":"898_CR40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.4103\/ijmr.IJMR_43_18","volume":"152","author":"R Jois","year":"2020","unstructured":"Jois R, Mukherjee S, Rajeswari S, Rath PD, Goyal V, Gupta D. Similar biologics in India: a story of access or potential for compromise? Indian J Med Res. 2020;152(5):456\u201367.","journal-title":"Indian J Med Res"},{"issue":"8","key":"898_CR41","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/acr2.11067","volume":"1","author":"S Kapoor","year":"2019","unstructured":"Kapoor S, Kaushik VV, Jain R, Rao VK, Gharia M. Real-life tolerability and effectiveness of adalimumab biosimilar in ankylosing spondylitis: the adalimumab biosimilar patient registry data. ACR Open Rheumatol. 2019;1(8):480\u20134.","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"898_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/JPBS.JPBS_167_18","volume":"11","author":"BR Meher","year":"2019","unstructured":"Meher BR, Balan S, Mohanty RR, Jena M, Das S. Biosimilars in India; current status and future perspectives. J Pharm Bioallied Sci. 2019;11(1):12\u20135.","journal-title":"J Pharm Bioallied Sci"},{"issue":"12","key":"898_CR43","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.22895","volume":"68","author":"H Jalal","year":"2016","unstructured":"Jalal H, O\u2019Dell JR, Bridges SL Jr, Cofield S, Curtis JR, Mikuls TR, et al. Cost-effectiveness of triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(12):1751\u20137.","journal-title":"Arthritis Care Res (Hoboken)."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00898-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-024-00898-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00898-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T03:16:20Z","timestamp":1728789380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-024-00898-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["898"],"URL":"https:\/\/doi.org\/10.1007\/s40258-024-00898-w","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"11 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dept. of Health Research Govt. of India funds the HTARC, ICMR-NIE Grant no: T.11011\/08\/2017-HR(Part-1)\/E-office -8025571 dated 27th Nov-2019. The funders played no role in the study's conception, execution, or manuscript preparation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All relevant data and materials supporting the findings of this study are included in the submitted files. Additional data or materials, if required, can be obtained upon reasonable request by contacting the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication (from patients\/participants)"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"M.H.: conceptualization, modeling, formal analysis, and original draft. A.S.: data curation, review, and editing. S.K.: data curation, review, and editing. K.R.: review and editing. K.V.: review and editing. B.S.B.: conceptualization, data curation, formal analysis, review, and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}